Q-omics provides the consensus-scored CAMK2N1 profile across patient tissues and cancer cell-line models. CAMK2N1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, CAMK2N1 is differentially expressed in 16, with the highest sampling consensus in THCA. Additionally, CAMK2N1 RNA expression shows 17,729 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight HNSC, THCA, and TGCT as cancer lineages where CAMK2N1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CAMK2N1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CAMK2N1 survival associations across molecular data types. CAMK2N1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CAMK2N1 RNA expression–survival associations across cancer types. High CAMK2N1 expression shows unfavorable associations in HNSC, LUSC and LUAD, but favorable associations in KIRC, SKCM and THCA. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for CAMK2N1 RNA expression.
This table summarizes CAMK2N1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 3. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for CAMK2N1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CAMK2N1 shows lower tumor expression in COAD, KIRC, LUAD and LUSC and higher tumor expression in THCA and LIHC. The THCA box plot shows higher CAMK2N1 RNA expression in tumor versus normal tissue (log2 FC = +3.714, t-test p < 0.001).
This table shows molecular features associated with CAMK2N1 in patient tissues and cancer cell lines. In patient samples, CAMK2N1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, CAMK2N1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and SOFT_TISSUE.
